

**Welcome to a three-day workshop and site visit on**

## **Interface Management of Pharmacotherapy**

Promoting Hospital-Primary Care Collaboration  
for Rational Use of Medicines – Workshop and Site Visit



**September 11–13, 2012, Stockholm, Sweden**  
**Stockholm Health Care Region**

**Aims:** To understand how multifaceted models can improve adherence to drug recommendations and quality of drug use across primary and hospital care. This will be achieved by:

- A:** International speakers and experts from WHO, Norway, Spain and the United Kingdom, as well as from the Drug and Therapeutics Committee Stockholm County Council and the Department of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden.
- B:** Presentation of different “Interface Models” including the Stockholm Model for the “Wise Use of Medicines”. The Stockholm Model will be supplemented by site visits with key personnel involved with the development, dissemination and implementation of this approach to gain practical experiences.
- C:** Participants exchanging experiences and discussions how the Rational Use of Medicines including Interface between hospitals and primary care can be improved in their countries with ever growing pressure on resources.

### **Target groups of participants:**

- senior medical and administrative managers and their advisors at hospitals, primary care boards, Ministries of Health, health authorities, health insurance agencies, in National Drug Policy programmes and researchers in the field
- chief physicians, hospital pharmacists, clinical pharmacologists and leaders of Drug and Therapeutics Committees

**Stockholm Model for Wise Use of Medicines:**

A comprehensive approach for improving the quality of drug use in a metropolitan healthcare region including:

- “Wise List” recommendations of medicines jointly for primary and hospital care
- Medicines policy strategy
- independent Drug and Therapeutics Committee with key role for respected drug experts with policy for “interest of conflicts”
- communication strategy with continuous medical education
- methods and tools for follow-up of medicines use
- systematic introduction of new expensive medicines
- operative resources
- e-pharmacological support at “point of care”

**Application:** The course/site visit is open to 25–30 participants from all over the world. Participants should apply for the course electronically to [wiselistmeetstockholm@sll.se](mailto:wiselistmeetstockholm@sll.se) where you also can ask for the application form. The application should contain information about:

- Personal details, including address, telephone and e-mail
- Rationale for attending
- Brief CV
- How the participant envisages covering his/her costs
- Any other important issues for consideration

Our ambition is to get back to those applicants who have been accepted as participants for the course by the beginning of August 2012. We will keep a waiting list for the course. Participants will be admitted to the course when the course fee has been paid.

**Course fee: 500 Euro.** International participants pay to account holder Karolinska Institutet Bank:

SEB, KG2 Team Staten, S-106 40 Stockholm, Sweden

IBAN NO: SE15 5000 0000 0543 9102 8247 SWIFT: ESSESESS

The course fee covers all course material as well as transport for the site visits.

Swedish participants pay to account holder Karolinska Institutet BG 5310-6654

**Host:** The Drug and Therapeutics Committee in Stockholm in collaboration with Department of Clinical Pharmacology at Karolinska Institutet and Karolinska University Hospital

**Accommodation:** Participants must cover their own accommodation costs. Hotel information will be provided on request.

**Scholarships:** Scholarships may be provided for participants from developing and emerging countries.

**International organizing group:** Lars L Gustafsson Stockholm (chair), Richard Laing WHO Geneva, Eva Andersén Karlsson Stockholm, Brian Godman Stockholm/Liverpool, Oyvind Melien Oslo, Sabine Vogler Vienna.

**Contact information:** Practical/organizational through Executive Secretary Paula Nordahl ([paula.nordahl@sll.se](mailto:paula.nordahl@sll.se)) and scientific through Associate Professor Eva Andersén Karlsson ([eva.andersen-karlsson@sll.se](mailto:eva.andersen-karlsson@sll.se)) and Professor Lars L Gustafsson ([lars-l.gustafsson@ki.se](mailto:lars-l.gustafsson@ki.se)).